Company intelligence / Profile preview

i-Lumen Scientific

Minneapolis/Bloomington, Minnesota, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~4
Development stage: Phase 2

Overview

i-Lumen Scientific is developing a non-invasive, software-based medical device that delivers pulsed microcurrent stimulation through the eyelid to treat patients with intermediate to advanced nonexudative age-related macular degeneration. The company has initiated at least four clinical trials, including a multicenter, randomized, sham-controlled double-masked trial ("i-SIGHT2") to evaluate safety and effectiveness in dAMD. No pivotal or commercial results have been published as of June 2025

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapy (pulsed microcurrent stimulation)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

i-Lumen AMD device

Phase 2

Indications: Dry age-related macular degeneration

Beyond the preview

Go deeper on i-Lumen Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on i-Lumen Scientific.

Explore the full profile